15 FebruaryMinistry of Health PO Box 5013 Wellington 6145 By email:

First Page		Document Content
Date: 2016-02-15 20:59:47 Health Medicine Pharmaceutical industry Pharmaceuticals policy Canadian law Health in Canada Natural health product Homeopathy Good manufacturing practice Medsafe Health freedom movement		15 FebruaryMinistry of Health PO Box 5013 Wellington 6145 By email: Add to Reading List Source URL: www.nzma.org.nz Download Document from Source Website File Size: 253,50 KB Share Document on Facebook

	2013 Annual Report HARNESSING A NEW ERA OF PARTNERSHIPS AND NETWORKS IN HEALTH INNOVATION THANK YOU TO OUR LEAD SPONSOR CANADA’S RESEARCH-BASED PHARMACEUTICAL COMPANIES DocID: 1vr6Q - View Document
	PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno DocID: 1vlwz - View Document
	Postdoctoral Position in Computational Toxicology Co-hosted by CCAAM/CaCVAM, Health Canada, and Environment and Climate Change Canada We are seeking a highly motivated and experienced Postdoctoral Research Fellow to DocID: 1vlea - View Document
	Community Support Contributions: 2014 AstraZeneca Canada is proud to provide support to many different charitable and non-profit organizations across Canada. In 2014, we invested almost $6 million in health initiatives w DocID: 1vkfE - View Document
	PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes    DocID: 1vjI2 - View Document